Read + Share
Amedeo Smart
Independent Medical Education
Butzkueven H, Trojano M, Kappos L, Spelman T, et al. Clinical outcomes in patients who discontinue natalizumab therapy after 2 years in the Tysabri((R)) Observational Program (TOP). Mult Scler 2021;27:410-419.PMID: 32406786
Email
LinkedIn
Facebook
Twitter
Privacy Policy